Compassionate use of radiation treatment for AMD approved
December 17th 2008NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.
Iluvien investigated for dry AMD
December 17th 2008A pilot study using Iluvien (an intravitreal insert delivering fluocinolone acetonide) to treat geographic atrophy secondary to age-related macular degeneration (AMD) has begun enrolling patients, according to a statement from Alimera Sciences Inc, the developer of Iluvien.
Intensive diabetes treatment reduces retinopathy risk
December 17th 2008Patients with type 1 diabetes who have been treated with intensive therapy have significantly lower incidences of retinopathy progression up to ten years, according to study results published in the December issue of the Archives of Ophthalmology.
Retinopathy screening costing too much money
December 10th 2008The lack of experience with evidence-based guidelines may be the reason for excessive follow-up after screening for hydroxychloroquine retinopathy, according to study results published in the December issue of the British Journal of Ophthalmology.
Best tools for measuring IOP in KC patients
December 3rd 2008The Pascal dynamic contour tonometer (DCT) and Reichert ocular response analyser (ORA) are the best tools for measuring corneal-compensated intraocular pressure (IOPcc) in patients with keratoconus (KC), according to study results published in the British Journal of Ophthalmology, December.
Avastin optimum dosing schedule defined
December 3rd 2008When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.
Glaucoma research focuses on neurodegeneration
November 26th 2008The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.